Fidson Healthcare Plc has entered into a partnership with US firms, Immune Therapeutics, GB Pharma and American Hospitals & Resort (AHAR) for the marketing
and distribution of a new product, LodonalTM, a patent-protected product that is indicated for the management of patients with immune-compromising
The partnership will leverage Fidson’s strong and experienced marketing base, robust distribution channels and efficient customer and technical support
services to promote LodonalTM in Nigeria. The distribution will become effective, upon completion of the ongoing NAFDAC approved 90‐day
Bridging trial evaluating the efficacy and safety of the product.
Managing Director, Fidson Healthcare Plc, Dr Fidelis Ayebae, expressed that “Fidson is truly excited about this collaboration with Immune Therapeutics
and GB Pharma/AHAR. We know that success in this industry going into the future will be dependent on having the right partnerships, and we could not
have asked for better partners at this stage of our growth. The international experience of Immune Therapeutics and GB Pharma/AHAR in different markets,
and their strong commitment to research will be of immense benefit to Fidson. Likewise, Fidson’s towering presence in the Nigeria Pharma space will
open a great door for the group to access one of the biggest and most rewarding markets in Africa”.
This partnership is another strategic approach by the management of Fidson Healthcare Plc, to further strengthen the company’s growth. It also comes on
the heels of the recent visit by President Muhammadu Buhari to the United States and President Barack Obama. The significance is monumental as a concrete
symbol of US-Nigerian commerce in a non-oil/gas related sector and a show case for the future of local manufacturing of quality pharmaceuticals on
the African continent.
President & CEO of GB Pharma, Dr. Gloria B. Herndon, said that “this is the crescendo of a great masterpiece that partnership of GB Pharma, American
Hospitals & Resorts, Immune Therapeutics, each with its distinct role. Fidson Healthcare markets and distributes throughout the extensive Nigerian
Network. We feel that Nigeria and US bilateral relationship will benefit from this amazing initiative that will enhance the health and wellbeing of
people all over the world. This is the spirit of collaboration that President Obama and President Buhari were talking about during the State visit”.
Fidson Healthcare Plc, recently recognized by Frost & Sullivan as the recipient of her ‘2014 Growth Excellence Leadership Award in the Nigerian Pharmaceutical
Industry, recorded sales of N9.7 billion in FY2014. The award was in recognition of the company’s consistent performance in the Nigerian pharmaceutical
sector, which has seen its revenues rise at a 15% CAGR over the last five years.
The Company has also won other corporate awards including the Financial Standard ‘Pharmaceutical Sector Leader’ Award in 2008 and the ‘Nigerian Pharmaceutical
Company of the Year’ at the Nigerian Healthcare Excellence Awards (NHEA) in 2014. Fidson’s definitive growth and consistent performance in the Nigerian
stock market also earned her CEO the 2014 BusinessDay Top 25 CEOs Award, which the company has won consecutively for two years.
To offer options in manufacturing and grow its product portflio, Fidson will be commissioning a N7.5 billion manufacturing plant this year. The new facility
will double the company’s production capacity and will also for the first time, add intravenous fluids to Fidson’s product portfolio. The facility
is built to conform to the World Health Organization (Geneva) current Good Manufacturing Practice (WHO-GMP) standards.
AHAR CEO, Dr. Richard Afonja, stated that “we are well positioned to effect this novel approach to treating HIV/AIDS and other immune compromised diseases
in the whole of Africa, starting with Nigeria. Bringing Fidson on board will enhance the facilitation of getting this much needed treatment approach
for these conditions”.
To achieve her strategic imperative of consistently improving her products and consolidate her market position, Fidson has continued to invest in research
and development across various disease areas. This has seen her record a number of firsts, key among which was becoming the first company in Sub-Saharan
Africa to manufacture antiretroviral drugs in 2005. The company has over 200 products across several therapeutic classes, which cut across anti-infectives,
gastrointestinal, antiretroviral, anti-malarial, cardiovascular, analgesic, haematinics and supplements.